Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data
Aclaris Therapeutics dropped 12.5 cents to $4.43 late Monday, underperforming broad biotech indexes after little recent news from the drugmaker. The SPDR S&P Biotech ETF lost 1.9%. The iShares Nasdaq Biotechnology ETF slid 1.4%. An ETF is a basket of securities trading like a single stock. Aclaris’ next shot with investors is coming up. The Wayne, Pennsylvania company said CEO Dr. Neal Walker and other executives will take part in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday at 2 p.m. ET. Its investor-relations site hasn’t posted anything newer than the May 28 release.